New hope for Hard-to-Treat liver disease: steroid combo trial launches
NCT ID NCT06591468
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding prednisone to standard UDCA treatment helps people with primary biliary cholangitis (PBC) who also have moderate to severe interface hepatitis, a type of liver inflammation. About 244 adults will be randomly assigned to receive either UDCA alone or UDCA plus prednisone. The goal is to see if the combination improves liver test results and reduces symptoms like fatigue and itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- prednisone and ursodeoxycholic acid (UDCA)
- What this could lead to
- If successful, this could offer a new treatment option for PBC patients with interface hepatitis who currently have limited effective therapies.
- What could go wrong
- This is a mid-stage trial with 244 participants, so results may not apply to all patients. Prednisone has known side effects like weight gain and infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- Can breathing and meditation ease PBC symptoms? new study says maybe.
- New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
- 3000-Patient study aims to predict PBC outcomes from blood tests